1 Dissolution Measurement System: Current State and Opportunities for Improvement Dr. Lucinda Buhse Director, Division of Pharmaceutical Analysis.

Slides:



Advertisements
Similar presentations
Stability Studies - Evaluation of Outcomes and Development of Documentation For Regulatory Submissions Bob Seevers.
Advertisements

Design and Calibration of a Dissolution Test Equipment Training Workshop on Dissolution, Pharmaceutical Product Interchangeability and Biopharmaceutical.
USP and Dissolution Testing Advisory Committee for Pharmaceutical Sciences 2 May 2005 Will Brown Staff Liaison to the Biopharmaceutics Expert Committee.
By Timina Olive Kayaviri Supervisor : Dr. Amugune
A Comparison of the Physical Properties of Some Commercial Aspirin Tablets Elaine Armstrong STEP.
Pharmacopoeial tests (USP)
Drug Delivery & Tissue Engineering Laboratory
Measuring and Managing Method Variability
World Health Organization
Division of Pharmaceutical Analysis Research in support of the Critical Path Dimensions Ensuring Safety Demonstrating Medical Utility Industrialization.
Determine impurity level in relevant batches1
World Health Organization
Chapter 5 Control Using Wireless Transmitters. Measurement and Control Data Sampling Rate  To achieve the best control response, the rule of thumb is.
Supplementary Training Modules on Good Manufacturing Practice
DSC instrument design and corresponding experimental methodology.
Dissolution Lynda Paleshnuik
World Health Organization
Challenges and Opportunities in Enhancement of the CMC Section of NDAs: Quality – by - Design Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical.
Learnings from Pre-approval Joint Inspection of a GSK QbD Product with US-FDA & EMA and the application of Continuous Verification 17 May 2011, Beijing,
Achieving and Demonstrating “Quality-by-Design” with Respect to Drug Release/dissolution Performance for Conventional or Immediate Release Solid Oral Dosage.
Accelerated Stability Testing
The following minimum specified ranges should be considered: Drug substance or a finished (drug) product 80 to 120 % of the test concentration Content.
Establishing Drug release/Dissolution Specifications – QBD Approach Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS, CDER Advisory.
Dissolution Lynda Paleshnuik Training workshop: Assessment of Interchangeable Multisource Medicines, Kenya, August 2009.
Module 1, Part 3: Process validation Slide 1 of 22 © WHO – EDM – 12/2001 Validation Part 3: Process validation Supplementary Training Modules on Good Manufacturing.
Dissolution and drug release testing
PHARMACEUTICS- IV (PHT 414 ) Dr. Shahid Jamil SALMAN BIN ABDUL AZIZ UNIVERSITY COLLEGE OF PHARMACY L /9/2015 Factors Affecting Drug Absorption (Dosage.
Analytical considerations in the dissolution testing of oral modified release products Graham Clarke Bristol-Myers Squibb Moreton, UK The British Pharmaceutical.
COMPARATIVE IN VITRO EVALUATION OF GENERIC CIPROFLOXACIN HYDROCHLORIDE TABLETS IN KENYA BY DANIEL MINYETO U59/81286/2012 Department of Pharmaceutical Chemistry.
Introduction to Topic #1: QbD approach for quality control and assurance of Dissolution Rate Ajaz S. Hussain, Ph.D. Deputy Director, Office of Pharmaceutical.
Quality control Lecture 1.
Chapter 13. Dissolution Phenomena
<701> DISINTEGRATION
Bureau of Drug and Narcotic Mechanical Calibration Temperature control  Calibrated thermometer  ˚ C Distance between the inside bottom of the.
1 Basis of the Proposed Tactical Plan for a QbD approach for Quality Control and Assurance of Dissolution Rate Ajaz S. Hussain, Ph.D. Deputy Director,
What Impact should ICH Q8 have on ICH Q6A Decision Trees?
The USP Performance Test Dissolution Systems Suitability Studies Walter W. Hauck, Ph.D. USP Consultant Presentation to Advisory Committee for Pharmaceutical.
Bioequivalence of Locally Acting Gastrointestinal Drugs: An Overview
NIPTE-FDA Collaborative Case Study On Model-based Design Space Development Across Scales & with Stability Considerations Design Space Integration 1.
Satish Mallya January 20-22, |1 | 2-3. Pharmaceutical Development Satish Mallya Quality Workshop, Copenhagen May 18-21, 2014 May 18-21,2014.
Formulation, Characterization of Pellets of Duloxetine Hydrochloride by Extrusion and Spheronization Prof. V. R. Sinha University Institute of Pharmaceutical.
1 G&H Meeting 4-5 th October, 2001 G&H Meeting 4-5 th October, 2001 Wellesbourne, UK Wellesbourne, UK WP 7 Pharmaceutics WP 7 Pharmaceutics Objectives.
Seminar on VALIDATION OF EQUIPMENT Prepared by: Jayesh P. Dobariya M.Pharm. Sem-II Roll no. 04 Department of Pharmaceutics, Maliba Pharmacy.
Blend Uniformity: Update Ajaz S. Hussain, Ph.D.. Background Issue: Assuring and documenting “adequacy of mixing” operations –PQRI’s Proposal Stratified.
Searching For Root Causes Under Pressure Using Data Visualization to Focus Investigations Dan Pilipauskas Pfizer Inc.
Introduction What is a Biowaiver?
Figure 5.1 A schematic representation of the boundary layer adjacent to the surface of a dissolving solid and the change in concentration of solute across.
Quality control Lecture 1.
Process Analytical Technology (PAT) Incorporating Process Analytical Technologies Framework into the plant to manage risk.
Dissolution tester Pharma test GembH (Germany) Pharma test GembH (Germany)
Types Of Transducers Resistive Position Transducer: The principle of the resistive position transducer is that the physical variable under measurement.
1/20 PRESENTED BY BRAHMABHATT BANSARI K. M. PHARM DEPARTMENT OF PHARMACEUTICS AND PHARMACEUTICAL TECHNOLGY L. M. COLLEGE OF PHARMACY.
Dissolution Test (U.S.P.): Two set of apparatus: Apparatus-1: A single tablet is placed in a small wire mesh basket attached to the bottom of the shaft.
- Pharmaceutical Equivalence Study
Introduction What is a Biowaiver?
SEMINAR ON…. In Vitro Dissolution Testing Models
Dr. Birgit Schmauser, BfArM, Bonn
Dissolution Process MOST CRITICAL method for End Process Testing of Solid Tablet Formulations.
Disintegration test & Dissolution test (official test)
This teaching material has been made freely available by the KEMRI-Wellcome Trust (Kilifi, Kenya). You can freely download,
Quality control Lecture 1.
Dissolution Process MOST CRITICAL method for End Process Testing of Solid Tablet Formulations.
USP and Dissolution Testing
Plan And Implement Investigations
USP and Dissolution Testing
Biopharmaceutics 4th year
Biopharmaceuitcs lab 6 In vitro dissolution study of per – oral tablet.
Evaluation of tablet dosage form 4) Disintegration
Quality control Lecture 1.
Evaluation of tablet dosage form 5) dissolution
Presentation transcript:

1 Dissolution Measurement System: Current State and Opportunities for Improvement Dr. Lucinda Buhse Director, Division of Pharmaceutical Analysis

2 Measurement System for Dissolution Rate Apparatus Current State of Calibration and Validation Sources of Variability Opportunities for Improvement

3 USP Dissolution Apparatus Apparatus 1 - Basket (37º) Apparatus 2 - Paddle (37º) Apparatus 3 - Reciprocating Cylinder (37º) Apparatus 4 – Flow-Through Cell (37º) Apparatus 5 – Paddle over Disk (32º), Transdermal Delivery System, use paddle and vessel from Apparatus 2 with a stainless steel disk assembly to hold the transdermal on the bottom of vessel. Apparatus 6, Cylinder (32º), Transdermal Delivery System, use Apparatus 1 except replace the basket shaft with a stainless steel cylinder element. Apparatus 7, Reciprocating Holder, for transdermal delivery systems and also a variety of dosage forms

4 Apparatus 1 Basket Apparatus 2 Paddle

5 Apparatus 3 (shown) Glass reciprocating cylinder Apparatus 7 Holders a) Reciprocating disk sample holder b) Transdermal system holder - angled disk (32º) c) Transdermal system holder - cylinder (32º) d) Oral extended-release tablet holder—rod, pointed for gluing e) Oral extended-release tablet holder—spring holder

6 Apparatus 4: Flow Through Cells

7 Current State for Dissolution Test Methods Most use: Apparatus 1 (Basket) or Apparatus 2 (Paddle) USP Equipment Set-Up and Calibration Criteria One point acceptance criteria for Immediate Release

8 Current State for Dissolution Test Methods Instrument Suitability –Choice of instrument –Mechanical Calibration (affecting hydrodynamics) –Calibrator Tablets (USP, not EP, BP or JP) Method Development / Validation

9 Current State: Instrument Suitability USP Mechanical Calibration Parameters include: Basket/Shaft Wobble (No significant wobble) Vessel/Shaft Centering (2 mm from centerline) Height check/Basket or Paddle Depth as measured at basket bottom or Paddle bottom ( mm) No significant vibration Rotational speed (+ 4%) Vessel Temperature (37.0   C) Basket Wobble (bottom rim) (+ 1mm)

10 Calibrator Tablets 1970’s : USP Calibrator Tablets Introduced –Disintegrating – 50 mg Prednisone (Upjohn) –Non Disintegrating – 300 mg Salicylic Acid (Hoffman LaRoche) 1997 : 50 mg Prednisone replaced with 10 mg Prednisone manufactured at University of Maryland 2004 : USP begins search for replacement for 10 mg Prednisone tablet USP: Both Calibrators on a given apparatus (i.e. 4 calibration tests if instrument is used for paddle and basket methods) JP, BP and EP: No calibrator tablets

11 Current State: Instrument Suitability Calibrators Every 6 months 10 mg Prednisone Tablet (Lot O0C056) Basket: 53 – 77% (now 51-81%) (DPA /- 5.4, n=36) Paddle: 27 – 48% (now 26-47%) (DPA /- 2.0, n=24) Salicylic Acid Tablet (Lot O) Basket: 23 – 29% Paddle: 17 – 26% Action with Out of Specification value Gets in the way of continuous improvement

12 Current State: Method Development / Validation Development –Discriminatory? Repeatable? Instrument – which one to use? Media Degassing Sinkers Validation: Determinative Step – Main Focus –Linearity and Recovery –Filtering –Stability of solutions –Interferences Even if we don’t understand development, we need to understand variability of our system (product, measurement, random)

13 Managing Variability Total variability σ 2 Total Assuming independent variable (if not independent for example interaction between measurement and product a covariance term needs to be included) σ 2 Total = σ 2 Product + σ 2 Measurement σ 2 Measurement = σ 2 Repeatability + σ 2 Reprodicibility Common Cause Vs. Special Cause variability Process capability: Customer Needs Process Ability

14 Current State: Variability Instrument Suitability –Apparatus Variability –Operator Set-up –Calibrator Assignment Variability Manufacturing of Calibrator Tablet Stability Instrument Set-up Degassing Product Specific –Media including degassing –Manufacturing –Dissolution equipment parameters (clips, sensitivity to set-up) –Sinkers –Determinative Step

15 Variability: Instrument Suitability Set-up Parameters: Shaft WobbleNo significant wobble ≤ 0.5 mm total run out Vessel/Shaft Centering2 mm from centerline 1 mm from centerline Height check/Basket or Paddle Depth as measured at Basket or Paddle bottom mm mm Vibration as measured at center of vessel support plate while operating at 100 rpm/head above plate, 900 ml medium in vessels No significant vibration ≤ 0.1 mil displacement Rotational speed+ 4%+ 1 rpm Basket Wobble (Bottom Rim)+ 1mm≤ 0.1mm total USPDPA

16 Used for determining water quality in agriculture, fisheries and industry A B Total Dissolved Gas and Oxygen Meter Variability: Media and Degassing

17 Total Gas Pressure and Oxygen Gas Pressure in Water Degassing by Various Methods Variability: Media and Degassing

18 Variability: Media and Degassing Product 1: paddle, 50 rpm, DI WaterProduct 2: basket, 100 rpm, pH 1.2 Product 3: paddle, 50 rpm, pH 7.4 buffer

19 pH 7.2pH 6.8 Variability: Media or Manufacturing?

20 What are the sources of variability at pH 6.8? Product handling during testing? Tablet to tablet differences? Instrumentation variation? –Vessel defects? –Inconsistent Centering? –RPM variations –Etc. Variability: Media or Manufacturing?

21 Microscope Images of the Coating Variability: Media or Manufacturing?

22 Variability Sinkers Product 1: paddle, 50rpm, DI water, off-center 10mm Sinkers are sometimes needed to hold product at the bottom of the dissolution vessel.

23 Variability Sinkers 60% - 72% Dissolved at 30 min. 66% ± 4% 89% – 99% Dissolved at 30 min. 95% ± 4% Commercial Sinker3 Wire Turns

24 Opportunities for Improvement Alternative regulatory approach to dissolution calibration and validation –Understand and control measurement system variability –Understand the product specific sources of variability –Understand relationship between physicochemical properties and dissolution results Understand the benefits and limitations of different dissolution apparatus – develop scientific criteria Investigate new approaches to assess product quality and availability Communication and training of FDA personnel

25 Alternative approach to dissolution calibration and validation Stringent Mechanical Calibration to replace the need for a calibrator tablet ID and Control all sources of variability –Apparatus Type including sinkers –Set-up Parameters –Media including degassing Understanding of interaction between instrument and product during pharmaceutical development If necessary, establish an internal calibrator (biobatch or clinical batch) for system suitability and stability Confirm suitability using Gauge R&R using pivotal clinical trial product or pivotal “bio-batch”

26 Gauge R&R Design Chance to characterize variability on an internal reference –Make it representative –Controlled manufacturing process For design include variables such as –Instrument –Personnel –Media

27 Understand the benefits and limitations of different dissolution apparatus Use design and development information to help choose an apparatus Model dissolution environments and understand hydrodynamics from first principles Look beyond apparatus 1 and 2 to alternative systems that may be easier to model and test (i.e., flow through?)

28 Investigate new approaches to assess product quality and availability New tools to assess product and media variability –Spectroscopy? NIR, RAMAN, Terahertz PAT including feedback loops First principles and modeling

29 Acknowledgements Terry Moore Zongming Gao Lawrence Yu Ajaz Hussain

30 % Dissolved Paddle Limits: % DPA: /- 2.0 n=24 Basket Limits: % DPA: /- 5.4 n=36 10-mg Prednisone Tablet DPA Distribution USP Limits